Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
about
Multiple myelomaThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaBortezomib (Velcadetrade mark) in the Treatment of Multiple MyelomaLenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaImproved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION studyProteasome inhibition and its therapeutic potential in multiple myelomaProteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.Proteasome inhibitors in the treatment of multiple myelomaMechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.Bone marrow microenvironment and the identification of new targets for myeloma therapy.Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapyNeuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewLong-term outcomes of different bortezomib-based regimens in Chinese myeloma patients.Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation.New therapies in multiple myeloma.Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.Treatment of newly diagnosed myeloma.Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.Front-line treatment in younger patients with multiple myeloma.Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.How best to use new therapies in multiple myeloma.Proteasome inhibitors in multiple myeloma: 10 years later.Diagnosis and therapy of multiple myeloma.Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
P2860
Q24655964-C5EAA683-6D48-456D-A14D-86D24734B1C3Q28539605-8726CC82-AEE6-439A-BB18-FA1696566C21Q33379044-55D0A265-1EB8-4031-99E2-0E57661898C6Q33389111-7ABD2359-324C-43E5-B6F5-1926B07BF338Q33408056-5970552D-AA72-4552-8962-DD471262E952Q33418300-32B93C89-4718-4F6F-BE07-C9E02199E926Q33632270-7DB41163-09AF-4BE0-837A-A12D7A593C77Q34063353-43994FB5-8A6F-4ED1-9713-2ECF1747B8EAQ34213649-F9820364-9711-466C-91AF-AEE79AA724C3Q34343036-148942ED-D9BE-430A-BA08-A80ADF4A2D4BQ34343763-D4A659FB-2541-4311-9B3C-CF8977267E3BQ34480149-E70D7906-FCAD-46A1-8367-DEDF314E934EQ34611676-8EA9E0CD-ECD0-422A-AC81-EBE70BE1C658Q35171777-3F01D395-CADC-4A55-8E3A-C18802D2CC28Q35802414-12DC50EB-EFE9-4C52-9573-A537AECD9172Q36141664-9B0A7F2E-FA7F-46CB-82B3-2E082A0039EFQ36162690-CF78E8FC-B6E4-442C-B33A-2283ABDEFDE5Q36162703-DED1C4EC-EE4A-4B35-AA51-06BADDEC88B7Q36209159-B245C048-CDF7-4384-9E97-5754AFBCD786Q36251560-1367F76A-D21A-4B0D-AC5A-8D780F097C5EQ36302859-6038C56D-501A-472B-9CC6-ACCE2B8090C1Q36408216-5BCFB61B-C121-4365-80D0-141022D3BCADQ36525841-65EB6C17-96F0-487C-8F7B-EE59FD1DB5A8Q36541807-E60E2E2C-0D31-4888-A48A-BDBBC1EC1306Q36777233-4691A799-1C6C-4B64-8D96-A8C15D093F59Q36834629-308CB139-F028-4529-89A9-6C8061D0D09EQ36986576-F6966D1D-DE13-4905-8AE3-567CBC3B8527Q37090630-31AC9BCB-CC42-4E56-8787-189A744F9713Q37162610-08594001-D73A-4074-BB0E-620D7297AE83Q37280739-F21290C3-373F-4C4F-81A3-CDD87916996DQ37324251-30CEAB02-DA7C-4EBE-AC59-7BFF329A0AA6Q37327618-76CA41B4-7CAB-42E5-9945-CDD72B433064Q37350545-0146F415-C510-42FE-9216-2F2320CB4AC6Q37457273-5D508B0F-981B-4FA8-B17D-B5CAA66318E2Q37523265-260E477A-D736-4B04-A4C1-AD83F2F9FBFCQ37623809-C2DABF75-CFE0-4975-B25D-35DFB8CBA7FEQ37723000-64D4655D-6F00-4640-A9E4-6D121B8D59ACQ38014395-2E5BA4CA-8729-4E28-A2C1-88BB18022CDEQ38107482-A11EAED5-9407-425F-B32A-0C267E30FC29Q39065872-5A2120DE-7245-4303-867A-3E2B44B37FA2
P2860
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@ast
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@en
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@nl
type
label
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@ast
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@en
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@nl
prefLabel
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@ast
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@en
Bortezomib plus dexamethasone ...... ults of an IFM phase II study.
@nl
P2093
P50
P1433
P1476
Bortezomib plus dexamethasone ...... sults of an IFM phase II study
@en
P2093
Anne-Marie Stoppa
Brigitte Pegourie
Cyrille Hulin
Hervé Avet-Loiseau
Jacques Troncy
Jean-Gabriel Fuzibet
Jean-Luc Harousseau
Lofti Benboubker
Marc Renaud
Michel Attal
P304
P577
2006-10-17T00:00:00Z